Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Influence of Lymphocyte Dynamics and Immune Profile on Outcomes of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma

  • By

  • Mansi R. Shah

  • Aishee Bag

  • Asis Shrestha

  • Yetunde Ogunsesan

  • Anup Trikannad

  • Sruthi Vellanki

  • Sanjay Muttineni

  • Hira Cheema

  • Syed Naqvi

  • Sasya Dronavalli

  • Samer Al Hadidi

  • Sharmilan Thanendrarjan

  • Maurizio Zangari

  • Frits van Rhee

  • Aniko Szabo

  • Rajshekar Chakraborty

  • Meera Mohan

  • Carolina Schinke

  • August 22, 2026

Share

  • 1

    Bispecific antibodies targeting BCMA or GPRC5D show overall response rates of 70% in relapsed/refractory multiple myeloma.

  • 2

    Baseline absolute lymphocyte count (ALC) and lymphocyte subset composition may reflect immune competence affecting bsAb treatment response.

  • 3

    Patients with high-risk cytogenetic abnormalities had lower response rates, while prior autologous stem cell transplant status influenced outcomes.

  • 4

    Lymphocyte kinetics showed a significant initial drop in ALC after bsAb initiation, with responders demonstrating faster recovery.

  • 5

    Exploratory analyses indicated that Day 30 lymphocyte subset measures could predict progression-free survival and overall survival.

Original Source(s)

Related Content